

1. The use of an inhibitor of the activity of MGDG synthase, for preparing a medicinal product against apicomplex parasites.
2. The use as claimed in claim 1, characterized in that said apicomplex parasite is selected from the group consisting of *Plasmodium*, *Toxoplasma* and *Eimeria*.
3. The use of an inhibitor of the activity of MGDG synthase, as a herbicide.
4. A method for screening and for selecting antiparasitic agents and/or herbicides, characterized in that it comprises:
- incubating a substance to be tested with an MGDG synthase or with a plastidial membrane isolated from a plant and
 - measuring the specific enzymatic activity, after said incubation.
5. The method as claimed in claim 4, characterized in that said MGDG synthase preferably has an initial specific activity of between 0.1 and 120 μmol of galactose incorporated/h/mg of protein.
6. The method as claimed in claim 4 or claim 5, characterized in that the MGDG synthase/substance to be tested incubation is carried out in an incubation medium containing a buffer adjusted to a pH of between 6 and 9, in the presence of detergents, of a reducing agent, of phosphatidylglycerol and of a salt.

1. The first step is to identify the problem. This involves understanding the current situation and what needs to be improved.

A D D
A B